Abstract
Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.
© 2017 American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily G, Member 2 / genetics
-
ATP Binding Cassette Transporter, Subfamily G, Member 2 / metabolism*
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Data Mining
-
Databases, Factual
-
Drug Development / methods*
-
Drug Discovery / methods*
-
Drug Resistance, Neoplasm
-
Evidence-Based Medicine / methods*
-
Humans
-
Models, Animal
-
Models, Theoretical
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Patient Safety
-
Pharmacogenomic Variants
-
Risk Assessment
-
Translational Research, Biomedical / methods*
Substances
-
ABCG2 protein, human
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
Antineoplastic Agents
-
Neoplasm Proteins